All In Biotech

Drug Trial Radar · NCT07734753

Impact of Alirocumab on Cardiovascular Events in Participants With Atherosclerotic Cardiovascular Disease But Without Prior Ischemic Events

Alirocumab and Cardiovascular Outcomes in Patients Without a Previous Myocardial Infarction or Stroke

Last checked: Nov 19, 2026Latest source record: Sep 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

4,006

Actual

Start

Jul 15, 2025

Primary completion

May 15, 2026

Study completion Aug 15, 2026

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
First posted
Jul 29, 2026

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To estimate ischemic event rates in individuals with established atherosclerotic cardiovascular disease (ASCVD) and no prior acute ischemic events, comparing alirocumab with no Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) inhibitor therapy, using a target trial emulation of routine clinical practice data.

Conditions

  • Atherosclerotic Cardiovascular Disease Without Prior Ischemic Events

Interventions

  • AlirocumabDrug

    The study will not administer any treatment, only observe the treatment as prescribed in routine clinical practice.

  • Comparator: No PCSK9i Therapy (monoclonal antibodies or small interfering RNA agents)Drug

    The study will not administer any treatment, only observe the treatment as prescribed in routine clinical practice.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Composite of Nonfatal Myocardial Infarction, Nonfatal Ischemic Stroke, or All-Cause MortalityTime frame: From index up to 5 years follow up

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Sanofi

    Amsterdam, Netherlands

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.